Cargando…
The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a survei...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604657/ https://www.ncbi.nlm.nih.gov/pubmed/37893035 http://dx.doi.org/10.3390/biomedicines11102661 |
_version_ | 1785126887300792320 |
---|---|
author | Nicolai, Eleonora Tomassetti, Flaminia Pelagalli, Martina Sarubbi, Serena Minieri, Marilena Nisini, Alberto Nuccetelli, Marzia Ciotti, Marco Pieri, Massimo Bernardini, Sergio |
author_facet | Nicolai, Eleonora Tomassetti, Flaminia Pelagalli, Martina Sarubbi, Serena Minieri, Marilena Nisini, Alberto Nuccetelli, Marzia Ciotti, Marco Pieri, Massimo Bernardini, Sergio |
author_sort | Nicolai, Eleonora |
collection | PubMed |
description | The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection. |
format | Online Article Text |
id | pubmed-10604657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106046572023-10-28 The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up Nicolai, Eleonora Tomassetti, Flaminia Pelagalli, Martina Sarubbi, Serena Minieri, Marilena Nisini, Alberto Nuccetelli, Marzia Ciotti, Marco Pieri, Massimo Bernardini, Sergio Biomedicines Article The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection. MDPI 2023-09-28 /pmc/articles/PMC10604657/ /pubmed/37893035 http://dx.doi.org/10.3390/biomedicines11102661 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nicolai, Eleonora Tomassetti, Flaminia Pelagalli, Martina Sarubbi, Serena Minieri, Marilena Nisini, Alberto Nuccetelli, Marzia Ciotti, Marco Pieri, Massimo Bernardini, Sergio The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title_full | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title_fullStr | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title_full_unstemmed | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title_short | The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up |
title_sort | antibodies’ response to sars-cov-2 vaccination: 1-year follow up |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604657/ https://www.ncbi.nlm.nih.gov/pubmed/37893035 http://dx.doi.org/10.3390/biomedicines11102661 |
work_keys_str_mv | AT nicolaieleonora theantibodiesresponsetosarscov2vaccination1yearfollowup AT tomassettiflaminia theantibodiesresponsetosarscov2vaccination1yearfollowup AT pelagallimartina theantibodiesresponsetosarscov2vaccination1yearfollowup AT sarubbiserena theantibodiesresponsetosarscov2vaccination1yearfollowup AT minierimarilena theantibodiesresponsetosarscov2vaccination1yearfollowup AT nisinialberto theantibodiesresponsetosarscov2vaccination1yearfollowup AT nuccetellimarzia theantibodiesresponsetosarscov2vaccination1yearfollowup AT ciottimarco theantibodiesresponsetosarscov2vaccination1yearfollowup AT pierimassimo theantibodiesresponsetosarscov2vaccination1yearfollowup AT bernardinisergio theantibodiesresponsetosarscov2vaccination1yearfollowup AT nicolaieleonora antibodiesresponsetosarscov2vaccination1yearfollowup AT tomassettiflaminia antibodiesresponsetosarscov2vaccination1yearfollowup AT pelagallimartina antibodiesresponsetosarscov2vaccination1yearfollowup AT sarubbiserena antibodiesresponsetosarscov2vaccination1yearfollowup AT minierimarilena antibodiesresponsetosarscov2vaccination1yearfollowup AT nisinialberto antibodiesresponsetosarscov2vaccination1yearfollowup AT nuccetellimarzia antibodiesresponsetosarscov2vaccination1yearfollowup AT ciottimarco antibodiesresponsetosarscov2vaccination1yearfollowup AT pierimassimo antibodiesresponsetosarscov2vaccination1yearfollowup AT bernardinisergio antibodiesresponsetosarscov2vaccination1yearfollowup |